Estimation of delay time in survival data with delayed treatment effect

References

• Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crinò, L., Blumenschein, G. R., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F., Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine 373:1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Chen, Y.-H. (2009). Weighted breslow-type and maximum likelihood estimation in semiparametric transformation models. Biometrika 96:591–600. doi:10.1093/biomet/asp032.
   Web of Science ®Google Scholar
• Chen, Y. (2010). Semiparametric marginal regression analysis for dependent competing risks under an assumed copula. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 72:235–251. doi:10.1111/rssb.2010.72.issue-2.
   Web of Science ®Google Scholar
• Fine, G. D. (2007). Consequences of delayed treatment effects on analysis of time-to-event endpoints. Drug Information Journal 41:535–539. doi:10.1177/009286150704100412.
   Web of Science ®Google Scholar
• He, P., Fang, L., Su, Z. (2013). A sequential testing approach to detecting multiple change points in the proportional hazards model. Statistics in Medicine 32:1239–1245. doi:10.1002/sim.5605.
   PubMed Web of Science ®Google Scholar
• He, P., Su, Z. (2015). A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects. Contemporary Clinical Trials Communications 1:28–31. doi:10.1016/j.conctc.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Hu, C., Tsodikov, A. (2014). Semiparametric regression analysis for time-to-event marked endpoints in cancer studies. Biostatistics 15:513–525. doi:10.1093/biostatistics/kxt056.
   PubMed Web of Science ®Google Scholar
• Kalbfleisch, J. D., Prentice, R. L. (1981). Estimation of the average hazard ratio. Biometrika 68:105–112. doi:10.1093/biomet/68.1.105.
   Web of Science ®Google Scholar
• Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., Mailliard, J. A. (1995). Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage iii colon carcinoma: A final report. Annals of Internal Medicine 122:321–326.
   PubMed Web of Science ®Google Scholar
• Rice, J. D., Tsodikov, A. (2017). Semiparametric time-to-event modeling in the presence of a latent progression event. Biometrics 73:463–472. doi:10.1111/biom.12580.
   PubMed Web of Science ®Google Scholar
• Schemper, M., Wakounig, S., Heinze, G. (2009). The estimation of average hazard ratios by weighted cox regression. Statistics in Medicine 28:2473–2489. doi:10.1002/sim.3623.
   PubMed Web of Science ®Google Scholar
• Tsodikov, A. (2003). Semiparametric models: A generalized self-consistency approach. Journal of the Royal Statistical Society Series B 65:759–774. doi:10.1111/1467-9868.00414.
   Google Scholar
• Xu, Z., Zhen, B., Park, Y., Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in Medicine 36:592–605. doi:10.1002/sim.7157.
   PubMed Web of Science ®Google Scholar
• Zeng, D., Lin, D. (2007). Maximum likelihood estimation in semiparametric regression models with censored data. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 69:507–564. doi:10.1111/rssb.2007.69.issue-4.
   Web of Science ®Google Scholar
• Zeng, D., Lin, D. (2010). A general asymptotic theory for maximum likelihood estimation in semiparametric regression models with censored data. Statistica Sinica 20:871.
   PubMed Web of Science ®Google Scholar
• Zucker, D. M., Lakatos, E. (1990). Weighted log rank type statistics for comparing survival curves when there is a time lag in the effectiveness of treatment. Biometrika 77:853–864. doi:10.1093/biomet/77.4.853.
   Web of Science ®Google Scholar